Browse by Medical Category
Accepting New Patients
As Program Director for Breast Medical Oncology, Dr. Ellisen oversees an integrated and multidisciplinary unit focused on excellence in patient care and groundbreaking clinical and translational research.
Go To Programs
Go To Programs
Go To Specialties
Dr. Ellisen is Professor of Medicine at Harvard Medical School and Program Director for Breast Medical Oncology at the Mass General Cancer Center. He is also co-Leader of the Breast Cancer Program at the Dana-Farber/Harvard Cancer Center. He received his undergraduate degree from Harvard University, MD and PhD degrees from Stanford University, and completed residency training, oncology fellowship training, and postdoctoral research training at Brigham and Women's Hospital, the Dana-Farber Cancer Institute, and Mass General, respectively. Dr. Ellisen is widely published in the fields of cancer biology, treatment and genetics. As Director of Breast and Ovarian Cancer Genetics at Mass General, Dr. Ellisen's clinical practice is focused on cancer risk assessment, cancer prevention and early detection. Research in Dr. Ellisen's laboratory is in the vanguard of revolutionizing cancer treatment through personalized cancer therapies. Dr. Ellisen is best known for his work on triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease.
View my most recent publications at PubMed
A study by researchers at three academic medical centers has shown that screening women with a suspected risk of hereditary breast or ovarian cancer for risk-associated genes other than BRCA1 and 2 provides information that can change clinical recommendations for patients and their family members.
The Massachusetts General Hospital Cancer Center is committed to advancing oncology care by tailoring treatment options to the individual cancer patient. The basic mission of the Translational Research Laboratory (TRL) is to provide rapid personalized genomic testing as an important component of routine care, thereby minimizing generalizations made in treatment decisions.
Back to Top